Long Nguyen-Hoang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Long Nguyen-Hoang has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Liona C. Poon
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR; Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China
8 shared publications - Daljit Singh Sahota
Department of Obstetrics and Gynaecology The Chinese University of Hong Kong Hong Kong SAR China
3 shared publications - Mingming Zheng
Nanjing Drum Tower Hospital affiliated to Nanjing University Medical School Nanjing China
3 shared publications - Sheng-Wen Steven Shaw
College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
3 shared publications Daljit S. Sahota
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR; Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China
2 shared publications- Huishu Liu
Department of Obstetrics, Guangzhou Women and Children's Medical Center Guangzhou Medical University Guangzhou China
2 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 68 (4) , 492-503
Determinants of preterm pre‐eclampsia following low‐dose aspirin prophylaxis: evidence from stepped‐wedge cluster randomized trial in Asia
Objectives: To identify potential risk factors – among maternal factors, pre‐eclampsia (PE)‐specific biomarkers and estimated risks derived from the first‐trimester Fetal Medicine Foundation (FMF) triple test – that are associated with the subsequent development of preterm PE, and to evaluate predictors of any‐onset PE using time‐to‐event analysis, in high‐risk women receiving low‐dose aspirin prophylaxis. Methods: This was a secondary analysis of a multicenter stepped‐wedge cluster randomized trial, including 18 maternity/diagnostic units from 10 regions in Asia between August 2019 and February 2022. The study population comprised women with a singleton pregnancy identified as being at high risk for preterm PE (estimated risk ≥ 1:100) according to the first‐trimester FMF triple test, who subsequently received low‐dose aspirin prophylaxis. A locally estimated scatterplot smoothing (LOESS) curve was applied initially to explore the relationship between the incidence of preterm PE and the estimated risk. Based on the trend observed in the LOESS curve, participants were categorized into five estimated risk groups: 1:2 to 1:5, 1:6 to 1:10, 1:11 to 1:20, 1:21 to 1:50 and 1:51 to 1:100. Logistic and Cox regression analyses were performed to identify independent predictors of preterm PE and to evaluate the risk of delivery with PE, respectively. Results: Among 2919 high‐risk pregnant women receiving aspirin prophylaxis, 280 (9.6%) developed PE, including 107 (3.7%) who developed preterm PE. Chronic hypertension (adjusted odds ratio (aOR), 1.835 (95% CI, 1.070–3.146)), mean arterial pressure (MAP) multiples of the median (MoM) > 1.149 (aOR, 2.162 (95% CI, 1.434–3.261)) and higher estimated risk were associated with higher odds of preterm PE. Compared to women with an estimated risk of 1:51 to 1:100, those with estimated risks of 1:2 to 1:5, 1:6 to 1:10 and 1:11 to 1:20 had a 16‐fold (aOR, 15.845 (95% CI, 8.166–30.746)), eight‐fold (aOR, 7.674 (95% CI, 3.925–15.004)) and three‐fold (aOR, 3.454 (95% CI, 1.802–6.622)) higher odds of developing preterm PE, respectively, whereas no significant difference was observed in those with an estimated risk of 1:21 to 1:50 (aOR, 1.343 (95% CI, 0.722–2.499)). On Cox regression analysis, chronic hypertension was associated with a three‐fold higher risk of delivering with PE (adjusted hazard ratio (aHR), 2.979 (95% CI, 2.154–4.120)), while MAP MoM > 1.149 increased the risk by 66% (aHR, 1.659 (95% CI, 1.304–2.111)). Compared with the reference group (estimated risk of 1:51 to 1:100), the risk of delivering with PE increased progressively across estimated risk groups, with aHRs of 1.435 (95% CI, 1.051–1.959), 2.408 (95% CI, 1.653–3.508), 4.058 (95% CI, 2.658–6.197) and 7.053 (95% CI, 4.588–10.841) for the 1:21 to 1:50, 1:11 to 1:20, 1:6 to 1:10, and 1:2 to 1:5 estimated risk groups, respectively. Conclusions: Chronic hypertension, elevated MAP and higher estimated risk are associated with the earlier development of PE in women identified as high risk by the first‐trimester FMF triple test, despite low‐dose aspirin prophylaxis. Incorporating these factors into the risk stratification framework may improve the detection of residual risk in first‐trimester screening and prevention strategies, thereby supporting the development of more effective preventive measures. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 27 September 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 68 (4) , 492-503
Open AccessDeterminants of preterm pre‐eclampsia following low‐dose aspirin prophylaxis: evidence from stepped‐wedge cluster randomized trial in Asia
Objectives: To identify potential risk factors – among maternal factors, pre‐eclampsia (PE)‐specific biomarkers and estimated risks derived from the first‐trimester Fetal Medicine Foundation (FMF) triple test – that are associated with the subsequent development of preterm PE, and to evaluate predictors of any‐onset PE using time‐to‐event analysis, in high‐risk women receiving low‐dose aspirin prophylaxis. Methods: This was a secondary analysis of a multicenter stepped‐wedge cluster randomized trial, including 18 maternity/diagnostic units from 10 regions in Asia between August 2019 and February 2022. The study population comprised women with a singleton pregnancy identified as being at high risk for preterm PE (estimated risk ≥ 1:100) according to the first‐trimester FMF triple test, who subsequently received low‐dose aspirin prophylaxis. A locally estimated scatterplot smoothing (LOESS) curve was applied initially to explore the relationship between the incidence of preterm PE and the estimated risk. Based on the trend observed in the LOESS curve, participants were categorized into five estimated risk groups: 1:2 to 1:5, 1:6 to 1:10, 1:11 to 1:20, 1:21 to 1:50 and 1:51 to 1:100. Logistic and Cox regression analyses were performed to identify independent predictors of preterm PE and to evaluate the risk of delivery with PE, respectively. Results: Among 2919 high‐risk pregnant women receiving aspirin prophylaxis, 280 (9.6%) developed PE, including 107 (3.7%) who developed preterm PE. Chronic hypertension (adjusted odds ratio (aOR), 1.835 (95% CI, 1.070–3.146)), mean arterial pressure (MAP) multiples of the median (MoM) > 1.149 (aOR, 2.162 (95% CI, 1.434–3.261)) and higher estimated risk were associated with higher odds of preterm PE. Compared to women with an estimated risk of 1:51 to 1:100, those with estimated risks of 1:2 to 1:5, 1:6 to 1:10 and 1:11 to 1:20 had a 16‐fold (aOR, 15.845 (95% CI, 8.166–30.746)), eight‐fold (aOR, 7.674 (95% CI, 3.925–15.004)) and three‐fold (aOR, 3.454 (95% CI, 1.802–6.622)) higher odds of developing preterm PE, respectively, whereas no significant difference was observed in those with an estimated risk of 1:21 to 1:50 (aOR, 1.343 (95% CI, 0.722–2.499)). On Cox regression analysis, chronic hypertension was associated with a three‐fold higher risk of delivering with PE (adjusted hazard ratio (aHR), 2.979 (95% CI, 2.154–4.120)), while MAP MoM > 1.149 increased the risk by 66% (aHR, 1.659 (95% CI, 1.304–2.111)). Compared with the reference group (estimated risk of 1:51 to 1:100), the risk of delivering with PE increased progressively across estimated risk groups, with aHRs of 1.435 (95% CI, 1.051–1.959), 2.408 (95% CI, 1.653–3.508), 4.058 (95% CI, 2.658–6.197) and 7.053 (95% CI, 4.588–10.841) for the 1:21 to 1:50, 1:11 to 1:20, 1:6 to 1:10, and 1:2 to 1:5 estimated risk groups, respectively. Conclusions: Chronic hypertension, elevated MAP and higher estimated risk are associated with the earlier development of PE in women identified as high risk by the first‐trimester FMF triple test, despite low‐dose aspirin prophylaxis. Incorporating these factors into the risk stratification framework may improve the detection of residual risk in first‐trimester screening and prevention strategies, thereby supporting the development of more effective preventive measures. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- Open Access
- 31 July 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 171 (1) , 32-44
Cancer and fertility management: FIGO best practice advice
Cancer diagnoses in patients of reproductive age require balancing urgent oncological treatment with the need to preserve fertility. This FIGO Best Practice Advice outlines key considerations for fertility management in this population given the rising cancer incidence among young women and the reproductive risks posed by cancer treatments. The guidance evaluates the impact of chemotherapy, radiotherapy, surgery, and emerging therapies—such as targeted agents and immunotherapies—on gonadal function and fertility. Established fertility preservation methods, including oocyte/embryo cryopreservation, sperm banking, and ovarian tissue freezing, are detailed alongside barriers to their adoption, such as cost and limited access. Early collaborative counseling with oncologists and fertility specialists is central to addressing timelines, psychological impacts, and priorities. Post‐treatment pathways, including assisted reproduction and surrogacy, are also explored. The guidance stresses the importance of integrating fertility‐sparing interventions and fertility preservation into cancer care while advocating for equitable access to resources. Further research is needed to refine preventive interventions, evaluate long‐term outcomes, and expand options for survivors globally. By prioritizing fertility preservation within oncological care, healthcare providers can better support the holistic needs of young individuals facing cancer.
- 31 July 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 171 (1) , 32-44
Open AccessCancer and fertility management: FIGO best practice advice
Cancer diagnoses in patients of reproductive age require balancing urgent oncological treatment with the need to preserve fertility. This FIGO Best Practice Advice outlines key considerations for fertility management in this population given the rising cancer incidence among young women and the reproductive risks posed by cancer treatments. The guidance evaluates the impact of chemotherapy, radiotherapy, surgery, and emerging therapies—such as targeted agents and immunotherapies—on gonadal function and fertility. Established fertility preservation methods, including oocyte/embryo cryopreservation, sperm banking, and ovarian tissue freezing, are detailed alongside barriers to their adoption, such as cost and limited access. Early collaborative counseling with oncologists and fertility specialists is central to addressing timelines, psychological impacts, and priorities. Post‐treatment pathways, including assisted reproduction and surrogacy, are also explored. The guidance stresses the importance of integrating fertility‐sparing interventions and fertility preservation into cancer care while advocating for equitable access to resources. Further research is needed to refine preventive interventions, evaluate long‐term outcomes, and expand options for survivors globally. By prioritizing fertility preservation within oncological care, healthcare providers can better support the holistic needs of young individuals facing cancer.
- 20 June 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (1) , 69-82
Pharmacogenomics and Pharmacokinetics of Aspirin in Preeclampsia Prevention
BACKGROUND: It has become evident that some women develop preeclampsia despite aspirin. This study aimed to examine how such aspirin nonresponsiveness develops in high-risk preeclampsia pregnancies by exploring the role of genetic polymorphisms and aspirin metabolism. METHODS: The study involved pregnant women who developed preeclampsia despite low-dose aspirin and those who did not. First, we conducted a pharmacogenomic association study exploring the association of potential genetic variants with aspirin nonresponsiveness. Next, we analyzed the rate of enzymatic aspirin hydrolysis in maternal plasma. The extent of placental exposure to acetylsalicylic acid and its bioactive metabolites, that is, salicylic acid and gentisic acid, was determined by liquid chromatography-mass spectrometry. The expressions of placental AMEs (aspirin metabolizing enzymes), that is, GLYAT (glycine-N-acyltransferase), UGT1A6 (UDP glucuronosyltransferase family 1 member A6), CYP2E1 (cytochrome P450 family 2 subfamily E member 1), and NAT2 (N-acetyltransferase 2) were analyzed by quantitative reverse transcription polymerase chain reaction, immunohistochemistry staining, and enzyme-linked immunosorbent assay. Finally, the effects of AMEs were further studied on HTR-8/SVneo (an immortalized human trophoblast cell line derived from first-trimester placenta) and hPCTB (human primary cytotrophoblast) cells. RESULTS: Our genetic study showed that single-nucleotide polymorphisms (SNPs) of genes involved in aspirin pharmacokinetics and pharmacodynamics were not associated with aspirin nonresponsiveness in preeclampsia. Rates of aspirin hydrolysis in maternal plasma and the concentrations of acetylsalicylic acid, salicylic acid, and gentisic acid in the placenta did not differ between aspirin-responsive and aspirin-nonresponsive women. Intriguingly, GLYAT was significantly upregulated in the aspirin-nonresponsive placenta and associated with aspirin nonresponsiveness. This overexpression of GLYAT was found to diminish the proangiogenic, anti-inflammatory, and antisenescence effects of salicylic acid in HTR-8/SVneo and hPCTB cells. CONCLUSIONS: Our study revealed that maternal genetic factors and plasma aspirin hydrolysis are not among the decisive factors in determining the effectiveness of low-dose aspirin in preventing preeclampsia among high-risk women. Instead, placental GLYAT appears to play a key role by limiting the effect of salicylic acid in the placenta.
- 20 June 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (1) , 69-82
Pharmacogenomics and Pharmacokinetics of Aspirin in Preeclampsia Prevention
BACKGROUND: It has become evident that some women develop preeclampsia despite aspirin. This study aimed to examine how such aspirin nonresponsiveness develops in high-risk preeclampsia pregnancies by exploring the role of genetic polymorphisms and aspirin metabolism. METHODS: The study involved pregnant women who developed preeclampsia despite low-dose aspirin and those who did not. First, we conducted a pharmacogenomic association study exploring the association of potential genetic variants with aspirin nonresponsiveness. Next, we analyzed the rate of enzymatic aspirin hydrolysis in maternal plasma. The extent of placental exposure to acetylsalicylic acid and its bioactive metabolites, that is, salicylic acid and gentisic acid, was determined by liquid chromatography-mass spectrometry. The expressions of placental AMEs (aspirin metabolizing enzymes), that is, GLYAT (glycine-N-acyltransferase), UGT1A6 (UDP glucuronosyltransferase family 1 member A6), CYP2E1 (cytochrome P450 family 2 subfamily E member 1), and NAT2 (N-acetyltransferase 2) were analyzed by quantitative reverse transcription polymerase chain reaction, immunohistochemistry staining, and enzyme-linked immunosorbent assay. Finally, the effects of AMEs were further studied on HTR-8/SVneo (an immortalized human trophoblast cell line derived from first-trimester placenta) and hPCTB (human primary cytotrophoblast) cells. RESULTS: Our genetic study showed that single-nucleotide polymorphisms (SNPs) of genes involved in aspirin pharmacokinetics and pharmacodynamics were not associated with aspirin nonresponsiveness in preeclampsia. Rates of aspirin hydrolysis in maternal plasma and the concentrations of acetylsalicylic acid, salicylic acid, and gentisic acid in the placenta did not differ between aspirin-responsive and aspirin-nonresponsive women. Intriguingly, GLYAT was significantly upregulated in the aspirin-nonresponsive placenta and associated with aspirin nonresponsiveness. This overexpression of GLYAT was found to diminish the proangiogenic, anti-inflammatory, and antisenescence effects of salicylic acid in HTR-8/SVneo and hPCTB cells. CONCLUSIONS: Our study revealed that maternal genetic factors and plasma aspirin hydrolysis are not among the decisive factors in determining the effectiveness of low-dose aspirin in preventing preeclampsia among high-risk women. Instead, placental GLYAT appears to play a key role by limiting the effect of salicylic acid in the placenta.
- 24 January 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 232 (6) , e213
Effect of aspirin on biomarker profile in women at high risk for preeclampsia
- 24 January 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 232 (6) , e213
Effect of aspirin on biomarker profile in women at high risk for preeclampsia
- Open Access
- 18 January 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 65 (2) , 173-182
Prediction of pre‐eclampsia using maternal hemodynamic parameters at 12 + 0 to 15 + 6 weeks
Objectives: To compare the maternal hemodynamic profile at 12 + 0 to 15 + 6 weeks' gestation in women who subsequently developed pre‐eclampsia (PE) and those who did not, and to assess the screening performance of maternal hemodynamic parameters for PE in combination with the Fetal Medicine Foundation (FMF) triple test, including maternal factors (MF), mean arterial pressure (MAP), uterine artery pulsatility index and placental growth factor.Methods: This was a prospective case–control study involving Chinese women with a singleton pregnancy who underwent preterm PE screening at 11 + 0 to 13 + 6 weeks' gestation using the FMF triple test, between February 2020 and February 2023. Women identified as being at high risk (≥ 1:100) for preterm PE by the FMF triple test were matched 1:1 with women identified as low risk (< 1:100) for maternal age ± 3 years, maternal weight ± 5 kg and date of screening ± 14 days. Two‐dimensional transthoracic echocardiography was performed at 12 + 0 to 15 + 6 weeks to evaluate maternal hemodynamic parameters (heart rate (HR), stroke volume (SV), cardiac output (CO) and systemic vascular resistance (SVR)). Maternal hemodynamic parameters were expressed as multiples of the median (MoM) values, determined by linear regression models to adjust for gestational age (GA) and MF. The distribution of log10 MoM values of maternal hemodynamic parameters in cases of PE and unaffected pregnancies, and the association between these hemodynamic parameters and GA at delivery, were assessed. The risks of preterm PE (delivery before 37 weeks) and any‐onset PE (delivery at any time) were reassessed using Bayes' theorem after maternal hemodynamic parameters were added to the FMF triple test. The screening performance for preterm PE and any‐onset PE was determined by the area under the receiver‐operating‐characteristics curve (AUC) and detection rate at a 10% fixed false‐positive rate (FPR). Differences in AUC (ΔAUC) were assessed using DeLong's test.Results: A total of 743 cases were analyzed, of whom 39 (5.2%) subsequently developed PE, including 29 (3.9%) cases of preterm PE and 10 (1.3%) cases of term PE. Mean log10 SVR MoM was significantly higher in cases of preterm PE and any‐onset PE compared with unaffected pregnancies. Mean log10 SV MoM and log10 CO MoM were significantly lower in cases of preterm PE and any‐onset PE compared with unaffected pregnancies. Mean log10 HR MoM was not significantly different between the study groups. Mean log10 CO MoM and log10 SVR MoM were not significantly correlated with GA at delivery in preterm PE and any‐onset PE. For the prediction of preterm PE and any‐onset PE, adding CO or SVR or replacing MAP with CO and SVR in the FMF triple test achieved an identical or greater AUC compared with the FMF triple test, but ΔAUC was not significantly different. In addition, adding CO or SVR or replacing MAP by CO and SVR in the FMF triple test did not improve the detection rate for preterm PE and any‐onset PE at a fixed FPR of 10%.Conclusions: Women with preterm PE or any‐onset PE exhibited increased SVR and decreased CO before the clinical manifestations of PE became apparent. These changes may serve as early indicators of cardiovascular maladaptation. However, assessment of maternal hemodynamics at 12 + 0 to 15 + 6 weeks does not enhance the screening performance for preterm PE and any‐onset PE of these parameters. The FMF triple test remains superior to other biomarker combinations for predicting PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 18 January 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 65 (2) , 173-182
Open AccessPrediction of pre‐eclampsia using maternal hemodynamic parameters at 12 + 0 to 15 + 6 weeks
Objectives: To compare the maternal hemodynamic profile at 12 + 0 to 15 + 6 weeks' gestation in women who subsequently developed pre‐eclampsia (PE) and those who did not, and to assess the screening performance of maternal hemodynamic parameters for PE in combination with the Fetal Medicine Foundation (FMF) triple test, including maternal factors (MF), mean arterial pressure (MAP), uterine artery pulsatility index and placental growth factor.Methods: This was a prospective case–control study involving Chinese women with a singleton pregnancy who underwent preterm PE screening at 11 + 0 to 13 + 6 weeks' gestation using the FMF triple test, between February 2020 and February 2023. Women identified as being at high risk (≥ 1:100) for preterm PE by the FMF triple test were matched 1:1 with women identified as low risk (< 1:100) for maternal age ± 3 years, maternal weight ± 5 kg and date of screening ± 14 days. Two‐dimensional transthoracic echocardiography was performed at 12 + 0 to 15 + 6 weeks to evaluate maternal hemodynamic parameters (heart rate (HR), stroke volume (SV), cardiac output (CO) and systemic vascular resistance (SVR)). Maternal hemodynamic parameters were expressed as multiples of the median (MoM) values, determined by linear regression models to adjust for gestational age (GA) and MF. The distribution of log10 MoM values of maternal hemodynamic parameters in cases of PE and unaffected pregnancies, and the association between these hemodynamic parameters and GA at delivery, were assessed. The risks of preterm PE (delivery before 37 weeks) and any‐onset PE (delivery at any time) were reassessed using Bayes' theorem after maternal hemodynamic parameters were added to the FMF triple test. The screening performance for preterm PE and any‐onset PE was determined by the area under the receiver‐operating‐characteristics curve (AUC) and detection rate at a 10% fixed false‐positive rate (FPR). Differences in AUC (ΔAUC) were assessed using DeLong's test.Results: A total of 743 cases were analyzed, of whom 39 (5.2%) subsequently developed PE, including 29 (3.9%) cases of preterm PE and 10 (1.3%) cases of term PE. Mean log10 SVR MoM was significantly higher in cases of preterm PE and any‐onset PE compared with unaffected pregnancies. Mean log10 SV MoM and log10 CO MoM were significantly lower in cases of preterm PE and any‐onset PE compared with unaffected pregnancies. Mean log10 HR MoM was not significantly different between the study groups. Mean log10 CO MoM and log10 SVR MoM were not significantly correlated with GA at delivery in preterm PE and any‐onset PE. For the prediction of preterm PE and any‐onset PE, adding CO or SVR or replacing MAP with CO and SVR in the FMF triple test achieved an identical or greater AUC compared with the FMF triple test, but ΔAUC was not significantly different. In addition, adding CO or SVR or replacing MAP by CO and SVR in the FMF triple test did not improve the detection rate for preterm PE and any‐onset PE at a fixed FPR of 10%.Conclusions: Women with preterm PE or any‐onset PE exhibited increased SVR and decreased CO before the clinical manifestations of PE became apparent. These changes may serve as early indicators of cardiovascular maladaptation. However, assessment of maternal hemodynamics at 12 + 0 to 15 + 6 weeks does not enhance the screening performance for preterm PE and any‐onset PE of these parameters. The FMF triple test remains superior to other biomarker combinations for predicting PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 14 November 2024
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 232 (6) , 561.e1-561.e20
Effect of aspirin on biomarker profile in women at high risk for preeclampsia
- 14 November 2024
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 232 (6) , 561.e1-561.e20
Effect of aspirin on biomarker profile in women at high risk for preeclampsia
- Top Cited PapersOpen Access
- 15 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (16) , 1223-1235
Implementation of First-Trimester Screening and Prevention of Preeclampsia: A Stepped Wedge Cluster-Randomized Trial in Asia
BACKGROUND: This trial aimed to assess the efficacy, acceptability, and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia in Asia. METHODS: Between August 1, 2019, and February 28, 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from 10 regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular 6-week intervals, one cluster was randomized to transit from nonintervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm preeclampsia using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm preeclampsia ≥1 in 100, received low-dose aspirin from <16 weeks until 36 weeks. RESULTS: Overall, 88.04% (42 897 of 48 725) of women agreed to undergo first-trimester screening for preterm preeclampsia. Among those identified as high-risk in the intervention phase, 82.39% (2919 of 3543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm preeclampsia between the intervention and non-intervention phases (adjusted odds ratio [aOR], 1.59 [95% CI, 0.91–2.77]). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm preeclampsia (aOR, 0.59 [95% CI, 0.37–0.92]). In addition, it correlated with 54%, 55%, and 64% reduction in the incidence of preeclampsia with delivery at <34 weeks (aOR, 0.46 [95% CI, 0.23–0.93]), spontaneous preterm birth <34 weeks (aOR, 0.45 [95% CI, 0.22–0.92]), and perinatal death (aOR, 0.34 [95% CI, 0.12–0.91]), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events. CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm preeclampsia is not associated with a significant reduction in the incidence of preterm preeclampsia. However, low-dose aspirin effectively reduces the incidence of preterm preeclampsia by 41% among high-risk women. The screen-and-prevent strategy for preterm preeclampsia is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm preeclampsia on a global scale. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03941886.
- 15 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (16) , 1223-1235
Top Cited PapersOpen AccessImplementation of First-Trimester Screening and Prevention of Preeclampsia: A Stepped Wedge Cluster-Randomized Trial in Asia
BACKGROUND: This trial aimed to assess the efficacy, acceptability, and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia in Asia. METHODS: Between August 1, 2019, and February 28, 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from 10 regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular 6-week intervals, one cluster was randomized to transit from nonintervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm preeclampsia using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm preeclampsia ≥1 in 100, received low-dose aspirin from <16 weeks until 36 weeks. RESULTS: Overall, 88.04% (42 897 of 48 725) of women agreed to undergo first-trimester screening for preterm preeclampsia. Among those identified as high-risk in the intervention phase, 82.39% (2919 of 3543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm preeclampsia between the intervention and non-intervention phases (adjusted odds ratio [aOR], 1.59 [95% CI, 0.91–2.77]). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm preeclampsia (aOR, 0.59 [95% CI, 0.37–0.92]). In addition, it correlated with 54%, 55%, and 64% reduction in the incidence of preeclampsia with delivery at <34 weeks (aOR, 0.46 [95% CI, 0.23–0.93]), spontaneous preterm birth <34 weeks (aOR, 0.45 [95% CI, 0.22–0.92]), and perinatal death (aOR, 0.34 [95% CI, 0.12–0.91]), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events. CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm preeclampsia is not associated with a significant reduction in the incidence of preterm preeclampsia. However, low-dose aspirin effectively reduces the incidence of preterm preeclampsia by 41% among high-risk women. The screen-and-prevent strategy for preterm preeclampsia is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm preeclampsia on a global scale. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03941886.
- Open Access
- 2 October 2023
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 62 (S1) , 82
OP13.07: Evaluation of screening performance of first trimester competing risk prediction model for small for gestational age in Asian population
- 2 October 2023
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 62 (S1) , 82
Open AccessOP13.07: Evaluation of screening performance of first trimester competing risk prediction model for small for gestational age in Asian population